论文部分内容阅读
目的探讨艾迪注射液对晚期原发性肝细胞癌(PCL)患者经肝动脉化疗灌注栓塞术(TACE)后血清甲胎蛋白(AFP)、血管内皮生长因子(VEGF)水平及生活质量的影响。方法 81例PCL患者随机分组,对照组40例予以TACE治疗,观察组41例在对照组基础上加用艾迪注射液治疗,比较两组临床疗效及AFP、VEGF水平、肿块面积,不良反应及生活质量(QOL)评分。结果观察组治疗总有效率90.24%(37/41)、总缓解率70.73%(29/41),高于对照组70.00%(28/40)、47.50%(19/40)(P<0.05);血清AFP、VEGF水平及肿块面积均小于对照组(P<0.05);不良反应发生率12.20%(5/41)高于对照组7.50%(3/40),胆无统计学差异(P>0.05);QOL评分高于对照组(P<0.05)。结论艾迪注射液可改善PCL患者血清AFP、VEGF水平及生活质量,缩小肿块面积,提高疗效,且安全性高。
Objective To investigate the effects of Aidi Injection on serum AFP, VEGF and quality of life in patients with advanced primary hepatocellular carcinoma (PCL) after transcatheter arterial chemoembolization (TACE) . Methods A total of 81 PCL patients were randomly divided into control group (n = 40) and TACE group (n = 41). Aidi Injection was used in 41 cases in the observation group. Clinical efficacy, AFP and VEGF levels, mass area, adverse reactions Quality of Life (QOL) score. Results The total effective rate of the observation group was 90.24% (37/41), the total remission rate was 70.73% (29/41), higher than that of the control group (70.00%, 47.50%, 19/40, P <0.05) (P <0.05). The incidence of adverse reactions was 12.20% (5/41) in the control group and 7.50% (3/40) in the control group, with no statistical difference between the two groups (P> 0.05); QOL score was higher than that of the control group (P <0.05). Conclusion Aidi injection can improve serum AFP, VEGF levels and quality of life in patients with PCL, reduce the mass area, improve the curative effect and have high safety.